Rheumatic Heart Disease Clinical Trial
Official title:
The Genetic Basis of Acquired Heart Disease in Africa
Background:
- An acquired heart disease is one that a person gets after they are born. Two of these are
rheumatic heart disease (RHD) and endomyocardial fibrosis (EMF). They are found more commonly
in people who live in Africa than in other places in the world. Researchers want to learn
more about these diseases. They especially want to know what role genes and other factors
play in them.
Objective:
- To identify genetic risk factors for RHD and EMF in sub-Saharan Africa.
Eligibility:
- Children and adults with RHD or EMF.
- Healthy volunteers over age 10.
Design:
- Participants will come from existing study groups in Uganda and Nigeria.
- Participants may be required to provide a sample of their DNA. They will do this with
either a blood or saliva sample or a swab of the mouth.
- Collected samples will be labeled with a code and sent to a lab in the United States for
analysis. Remaining portions of participants samples will be stored for an unlimited
period of time. They may be used in future studies.
- Some genetic and health information from participants might be placed into one or more
scientific databases.
- Participant names and identifying information will be kept private. But there is a small
chance someone could trace them from their genetic information.
Recent advances in genomic techniques are making possible a new wave of genetic discovery in many complex diseases. However, the genetic risk factors for two forms of acquired heart disease that are particularly common in Africa - rheumatic heart disease (RHD) and endomyocardial fibrosis (EMF) remains unknown. In this application, we propose to evaluate genetic risk factors for rheumatic heart disease (RHD) and endomyocardial fibrosis (EMF). A number of factors should facilitate the identification of genetic risk variants underlying the two conditions. First, both forms of acquired heart disease are endemic to sub-Saharan Africa (SSA). Second, affected patients and those who do not develop the conditions share a common environment. Finally, the availability of high density SNP arrays to capture common and rare variation makes the characterization of genomic variation better than ever. Patients will be enrolled at the Uganda Heart Institute in Kampala, Uganda, and at the College of Medicine, University of Lagos, Nigeria, with the potential to include other African sites. Genomic studies will be done at the NIH. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05991219 -
Screening and Secondary Prevention Rheumatic Heart Disease Study
|
||
Completed |
NCT02661763 -
Rheumatic Heart Disease Study in Lusaka
|
N/A | |
Completed |
NCT02188862 -
Genetic Susceptibility to Rheumatic Heart Disease in the Pacific Region
|
N/A | |
Completed |
NCT01178710 -
Effect of Simvastatin on Cardiac Function
|
N/A | |
Recruiting |
NCT05693545 -
GOALIE: Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent RHD Trial
|
Phase 2 | |
Completed |
NCT06150274 -
Comparison of Wire Assisted Percutaneous Balloon Mitral Valvulotomy With Standard Inoue Balloon Valvulotomy
|
N/A | |
Terminated |
NCT03926156 -
RIvoraxaban in Mitral Stenosis
|
Phase 3 | |
Recruiting |
NCT05783375 -
Accelerating Delivery of rheUmatic Heart Disease Preventive iNterventions in Northern Uganda
|
N/A | |
Completed |
NCT02474108 -
Surgical Prevention of Atrial Fibrillation in Patients With Rheumatic Mitral Valve Lesion and Left Atrium Enlargement
|
N/A | |
Recruiting |
NCT04556188 -
The Clinical Influence of Developing a Sustainable Cardiac Surgery Service to Reduce the Burden of Rheumatic Heart Disease in Sub-Saharan Africa
|
||
Recruiting |
NCT03991910 -
The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients
|
Phase 3 | |
Active, not recruiting |
NCT03346525 -
Determining the Impact of Penicillin in Latent RHD: The GOAL Trial
|
Phase 2 | |
Recruiting |
NCT05504928 -
Effectiveness of a School-centered Prevention Program on Prevalence of Latent Rheumatic Heart Disease
|
N/A | |
Not yet recruiting |
NCT03549052 -
Right Ventricular Echo Assessment in Mitral Valve Replacement
|
||
Recruiting |
NCT05487469 -
Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass
|
N/A | |
Completed |
NCT05276999 -
Rheumatic Heart Disease Community Streptococcal Treatment Program "RESET"
|
N/A | |
Completed |
NCT05668611 -
Train the Trainer Curriculum to Scale up AI Supported Echo for RHD Screening in a Public Health System
|
N/A | |
Active, not recruiting |
NCT05211024 -
A Long-term Follow up Study for Patients Who Participated in the GOAL Trial (GOAL-Post)
|
||
Withdrawn |
NCT02832531 -
INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority
|
Phase 3 | |
Completed |
NCT01794884 -
Validity Study of Glutamine to Improve Cardiac Function in Cardiac Surgery
|
Phase 2 |